Drug Trial Radar · NCT03443414
Dose Ranging Study of RPL554 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Last checked: Nov 20, 2026Latest source record: Jun 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
405
Actual
Start
Jun 1, 2017
Primary completion
Jan 23, 2018
Study completion Feb 7, 2018
Sponsor
- Lead sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAIndustry
- Sponsor type
- Industry
- First posted
- Feb 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study investigates the effect of 4 weeks of twice daily treatment of four different doses of RPL554 (a phosphodiesterase \[PDE\]3/4 inhibitor) or placebo in patients with moderate to severe chronic obstructive pulmonary disease (COPD). Patients will be equally allocated to one of the five treatment options.
Conditions
- COPD
Interventions
RPL554 suspensionDrug
A dual PDE3/PDE 4 inhibitor
PlaceboDrug
Placebo solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline in Peak FEV1 (Over 3 Hours) at Week 4Time frame: Baseline (pre-dose, Visit 2) and Week 4 (Visit 6).
Locations
49 sites in 6 countries. Site status is shown where the registry gives one.
Clinic for pneumonology
Pleven, Bulgaria
SHATPPD-Ruse EOOD
Rousse, Bulgaria
Fifth MHAT - Sofia EAD
Sofia, Bulgaria
MHAT 'Lyulin', EAD
Sofia, Bulgaria
NMTH Tsar Boris III
Sofia, Bulgaria
UMHAT 'Alexandrovska' EAD
Sofia, Bulgaria
UMHAT 'Sveta Anna' AD
Sofia, Bulgaria
Medical Center Nov
Stara Zagora, Bulgaria
MediTrial s.r.o.
Jindřichův Hradec, Czechia
Plicni stredisko Teplice
Teplice, Czechia
Aerzte fuer Lungen- und
Berlin, Germany
Charite Campus Mitte
Berlin, Germany
emovis GmbH
Berlin, Germany
Studienpraxis Berlin
Berlin, Germany
IKF Pneumologie GmbH & Co. KG
Frankfurt, Germany
Praxis Dr. Keller
Frankfurt, Germany
Inamed GmbH
Gauting, Germany
PRI Pulmonary Research
Großhansdorf, Germany
Hamburger Institut fuer
Hamburg, Germany
Gemeinschaftspraxis Dres
Koblenz, Germany
POIS Leipzig GbR
Leipzig, Germany
SALVUS UG Centre for Clinial Trials
Leipzig, Germany
KLB Gesundheitsforschung
Lübeck, Germany
Pneumologische Praxis Pasing
München, Germany
Pneumologie Odeonsplatz
Munich, Germany
Ballenberger Freytag Wenisch
Neu-Isenburg, Germany
Dr. Christian Schlenska
Peine, Germany
CERMED
Bialystok, Poland
Indywidualna Specjalistyczna
Bialystok, Poland
KLIMED Marek Klimkiewicz
Bychawa, Poland
Silmedic sp. z o.o.
Katowice, Poland
Grazyna Pulka Specjalistyczny
Krakow, Poland
Malopolskie Centrum Alergologii
Krakow, Poland
Centrum Terapii Wspólczesnej
Lodz, Poland
Uniwersytecki Szpital Klin
Lodz, Poland
NZOZ Alergo-MEDSpecjalistyczna
Poznan, Poland
ETG Network Sp z o o
Skierniewice, Poland
Centrum Medyczne Pratia
Warsaw, Poland
Mazowieckie Centrum Medyczne
Warsaw, Poland
Centrum Badan Klinicznych
Wroclaw, Poland
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.